Back to top
more

BioMarin Pharmaceutical (BMRN)

(Real Time Quote from BATS)

$69.48 USD

69.48
164,342

-0.62 (-0.88%)

Updated Oct 2, 2024 10:58 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Harmony Biosciences Holdings, Inc. (HRMY) Lags Q3 Earnings Estimates

by Zacks Equity Research

Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of -5.97% and 11.39%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights Bristol Myers, PTC Therapeutics, Beam Therapeutics and BioMarin Pharmaceutical

by Zacks Equity Research

Bristol Myers, PTC Therapeutics, Beam Therapeutics and BioMarin Pharmaceutical are included in this Analyst Blog.

Biotech Stock Roundup: BMY's Q3 Results, PTCT Up on Deal, BEAM's Restructuring News

by Zacks Equity Research

Earnings and other updates from Bristol Myers (BMY) and PTC Therapeutic (PTCT) are in focus in the biotech sector.

Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Merus N.V. (MRUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will the Medicare Unit Aid Molina Healthcare's (MOH) Q3 Earnings?

by Zacks Equity Research

Molina Healthcare's (MOH) Q3 results are expected to benefit on growing premiums and an expanding customer base within its Medicaid and Medicare businesses, partly offset by increased medical costs.

Elevance Health (ELV) Q3 Earnings Beat on Carelon Unit Strength

by Zacks Equity Research

Membership growth in the Medicare Advantage business and strong segmental performance aid Elevance Health's (ELV) Q3 results. An encouraging 2023 earnings guidance also bodes well for investors.

Why BioMarin (BMRN) Could Beat Earnings Estimates Again

by Zacks Equity Research

BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

CHMP Endorses BioMarin's (BMRN) Voxzogo for Use in Infants

by Zacks Equity Research

A final decision study on BioMarin's (BMRN) Voxzogo to treat children above four months with achondroplasia is expected before year's end.

Why Is Seattle Genetics (SGEN) Up 6.5% Since Last Earnings Report?

by Zacks Equity Research

Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Incyte (INCY) Down 0.7% Since Last Earnings Report?

by Zacks Equity Research

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BioMarin (BMRN) Q2 Earnings & Sales Top, Voxzogo Drives Sales

by Zacks Equity Research

BioMarin (BMRN) beats on earnings and sales estimates in the second quarter on the back of robust demand for Voxzogo.

BioMarin (BMRN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

BioMarin Pharmaceutical (BMRN) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

BioMarin (BMRN) delivered earnings and revenue surprises of 14.89% and 0.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stock Roundup: BMRN's Gene Therapy Gets Approval, SGTX Up on Buyout by LLY

by Zacks Equity Research

Regulatory and acquisition updates from BioMarin (BMRN) and Sigilon (SGTX) are in focus in the biotech sector.

BioMarin (BMRN) Gets FDA Nod for Hemophilia A Gene Therapy

by Zacks Equity Research

Following FDA's approval, BioMarin's (BMRN) Roctavian becomes the first gene therapy for treating severe hemophilia A.

Pfizer (PFE) Posts Upbeat Data From Hemophilia Drug Study

by Zacks Equity Research

Data from a late-stage study shows that treatment with Pfizer's (PFE) experimental anti-TFPI inhibitor led to a significant reduction in annualized bleeding rate in hemophilia A and B patients.

Why Is BioMarin (BMRN) Down 4% Since Last Earnings Report?

by Zacks Equity Research

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PTC Therapeutics' (PTCT) PKU Drug Meets Study Goal, Up 7.6%

by Zacks Equity Research

Data from a late-stage study data shows that treatment with PTC Therapeutics' (PTCT) sepiapterin led to a significant reduction in Phe levels in PKU patients. Post the news, share price rises.

New Strong Sell Stocks for May 1st

by Zacks Equity Research

AOMR, BMRN and CUTR have been added to the Zacks Rank #5 (Strong Sell) List on May 1, 2023.

BioMarin (BMRN) Q1 Earnings Top, Voxzogo Drives Sales

by Zacks Equity Research

BioMarin (BMRN) reports encouraging first-quarter results, wherein both earnings and sales beat estimates. The rapid uptake of Voxzogo boosts revenues.

BioMarin (BMRN) Reports Q1 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

BioMarin Pharmaceutical (BMRN) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

BioMarin (BMRN) delivered earnings and revenue surprises of 39.53% and 4.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PBE